Hematology

A large-scale US study reveals that 34% of sickle cell disease patients are readmitted within 30 days of hospital discharge, nearly triple the rate of non-SCD patients.

In a major study presented at EHA, Noella Collado-Gisbert demonstrated that residual disease kinetics are a strong predictor of survival in multiple myeloma.

Recognised with an EHA Young Abstract award, Hangjie Fu’s study reveals that ellagic acid significantly mitigates liver injury caused by iron overload.

The Phase II CONCEPT trial has demonstrated that an isatuximab-based combination therapy achieves unprecedented rates of minimal residual disease negativity in patients with high-risk newly diagnosed multiple myeloma.

A large European analysis confirms circulating tumour cells (CTCs) as an independent prognostic biomarker in newly diagnosed multiple myeloma.

A new analysis of early total therapy clinical trials has revealed that up to one-third of patients with newly diagnosed multiple myeloma may achieve long-term survival.

A new UK clinical trial has found that children undergoing stem cell transplants may safely receive fewer blood transfusions.